MPS MEMBER TICKET ONLY Psychopharmacology Update: 2019

Event Information

Share this event

Date and Time

Location

Location

The Conference Center at Sheppard Pratt

6501 North Charles Street

Baltimore, MD 21204

View Map

Refund Policy

Refund Policy

Contact the organizer to request a refund.

Eventbrite's fee is nonrefundable.

Event description
Please join us for the Maryland Psychiatric Society’s Annual Psychopharmacology Update in Baltimore!

About this Event

Please join us for the Maryland Psychiatric Society’s Annual Psychopharmacology Update in Baltimore! All of our dynamic sessions will be presented by a slate of distinguished faculty on a wide variety of topics tailored towards psychiatrists and mental health clinicians who need the most up-to-date information available. The course is meant for all clinicians who prescribe psychotropic medications, and will address indications, contraindications, management of adverse events and more. It includes a focus on complex and challenging conditions, atypical presentations and special populations throughout the life cycle.

Agenda:

8:30AM Breakfast and Registration

9:00 Esketamine for Treatment Resistant Depression: How eSpecial is eSpecial K: Evolution, Revolution or Fashion? : Adam Kaplin, MD, PhD

10:00 Brexanolone: Clinical Considerations and Future Research Directions: Lindsay Standeven, MD

11:00 BREAK

11:15 The Past and Future of Vagus Nerve Stimulation for Treatment Resistant Depression : Scott Aaronson, MD

12:15 LUNCH

1:15 Psilocybin Treatment of Depression & Tobacco Addiction:Matt Johnson, Ph.D.

2:15 Optimizing Psychiatric Treatment Regimens to Treat Pain : Liz Prince, DO

3:15 BREAK

3:30 Deep TMS for Obsessive Compulsive Disorder: Geoff Grammer, MD

Goals/Objectives:

At the end of this educational activity, the learner will be able to:

Describe the features of a treatment resistant depression (TRD)

Identify potential candidates most likely to benefit from vagus nerve stimulation (VNS) for depression

Differentiate between scales rating severity of depression from scales evaluating quality of life and how each should impact on clinical decision making.

Describe differences in magnetic field generations with different TMS coil types

Name areas of the brain implicated in OCD and affected by deep TMS

Define outcomes in the deep TMS for OCD clinical trial that was considered in FDA approval

Identify disorders which are being investigator regarding treatment with psilocybin

Identify risks of administering psilocybin

Describe safety mechanisms for mitigating risks in psilocybin research

Learn the risks, benefits and alternatives to the use of esketamine for treatment resistant depression.

Understand the presumed basic mechanism of action of low dose esketamine and why that results in unique clinical characteristics of this novel, recently approved antidepressant therapy

Describe to patients the basis for the approval by the FDA of this treatment, and what the risks are and side effects, as well as unique clinical applications

Identify the somatic and psychiatric relative contraindications to the use of esketamine

Discuss the epidemiology of perinatal depression and anxiety

Understand of biological background that fueled interest in Brexanalone

Review scientific literature on Brexanalone and strength of findings

List clinical challenges in Brexanalone administration

Understand how pain and psychiatric illness are related

Discuss how pain medications relate to psychiatric illness

Identify psychiatric treatments that can impact pain

Review management strategies for patients with psychiatric illness and pain disorders

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of American Psychiatric Association (APA) and Maryland Psychiatric Society (MPS).   The APA is accredited by the ACCME to provide continuing medical education for physicians.  The APA designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s) TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for a maximum of 6 hours of Category I Continuing Education for Social Workers by the Maryland Board of Social Workers.

This activity is approved for a maximum of 6 hours of Continuing Education for Psychologists by the Maryland Board of Examiners for Psychologists.

Date and Time

Location

The Conference Center at Sheppard Pratt

6501 North Charles Street

Baltimore, MD 21204

View Map

Refund Policy

Contact the organizer to request a refund.

Eventbrite's fee is nonrefundable.

Save This Event

Event Saved